Drug Type Small molecule drug |
Synonyms FGFR3 Selective + [4] |
Target |
Mechanism FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR3 Mutant Neoplasms | Phase 1 | GB | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | JP | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | CA | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | ES | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | FR | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | AU | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | KR | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | NO | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | US | 12 Jan 2023 | |
FGFR3 Mutant Neoplasms | Phase 1 | DE | 12 Jan 2023 |